202 related articles for article (PubMed ID: 37865779)
1. Distinguishing the effects of systemic CSF1R inhibition by PLX3397 on microglia and peripheral immune cells.
Okojie AK; Uweru JO; Coburn MA; Li S; Cao-Dao VD; Eyo UB
J Neuroinflammation; 2023 Oct; 20(1):242. PubMed ID: 37865779
[TBL] [Abstract][Full Text] [Related]
2. Concentration-dependent effects of CSF1R inhibitors on oligodendrocyte progenitor cells ex vivo and in vivo.
Liu Y; Given KS; Dickson EL; Owens GP; Macklin WB; Bennett JL
Exp Neurol; 2019 Aug; 318():32-41. PubMed ID: 31029597
[TBL] [Abstract][Full Text] [Related]
3. Early posttraumatic CSF1R inhibition via PLX3397 leads to time- and sex-dependent effects on inflammation and neuronal maintenance after traumatic brain injury in mice.
Wang Y; Wernersbach I; Strehle J; Li S; Appel D; Klein M; Ritter K; Hummel R; Tegeder I; Schäfer MKE
Brain Behav Immun; 2022 Nov; 106():49-66. PubMed ID: 35933030
[TBL] [Abstract][Full Text] [Related]
4. Limitations of PLX3397 as a microglial investigational tool: peripheral and off-target effects dictate the response to inflammation.
Claeys W; Verhaege D; Van Imschoot G; Van Wonterghem E; Van Acker L; Amelinck L; De Ponti FF; Scott C; Geerts A; Van Steenkiste C; Van Hoecke L; Vandenbroucke RE
Front Immunol; 2023; 14():1283711. PubMed ID: 38077359
[TBL] [Abstract][Full Text] [Related]
5. CSF1R inhibitor PLX3397 depletes microglia in Mongolian gerbil Meriones unguiculatus, but not in syrian hamster Mesocricetus auratus.
Sato RY; Zhang Y; Kotake KT; Onishi H; Ito S; Norimoto H; Zhou Z
J Pharmacol Sci; 2024 Jun; 155(2):29-34. PubMed ID: 38677783
[TBL] [Abstract][Full Text] [Related]
6. Effect of the CSF1R inhibitor PLX3397 on remyelination of corpus callosum in a cuprizone-induced demyelination mouse model.
Tahmasebi F; Pasbakhsh P; Mortezaee K; Madadi S; Barati S; Kashani IR
J Cell Biochem; 2019 Jun; 120(6):10576-10586. PubMed ID: 30628737
[TBL] [Abstract][Full Text] [Related]
7. Dynamic changes in microglia in the mouse hippocampus during administration and withdrawal of the CSF1R inhibitor PLX3397.
Wang Q; Wang YY; Pu WJ; Ma X; Ni RJ
J Anat; 2023 Sep; 243(3):394-403. PubMed ID: 37038887
[TBL] [Abstract][Full Text] [Related]
8. Underestimated Peripheral Effects Following Pharmacological and Conditional Genetic Microglial Depletion.
Han J; Fan Y; Zhou K; Zhu K; Blomgren K; Lund H; Zhang XM; Harris RA
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33203068
[TBL] [Abstract][Full Text] [Related]
9. Partial reduction of microglia does not affect tau pathology in aged mice.
Bennett RE; Bryant A; Hu M; Robbins AB; Hopp SC; Hyman BT
J Neuroinflammation; 2018 Nov; 15(1):311. PubMed ID: 30413160
[TBL] [Abstract][Full Text] [Related]
10. Colony-Stimulating Factor-1 Receptor Inhibition Transiently Attenuated the Peripheral Immune Response to Experimental Traumatic Brain Injury.
Giordano KR; Saber M; Green TRF; Rojas-Valencia LM; Ortiz JB; Murphy SM; Lifshitz J; Rowe RK
Neurotrauma Rep; 2023; 4(1):284-296. PubMed ID: 37139183
[TBL] [Abstract][Full Text] [Related]
11. Depletion of microglia with PLX3397 attenuates MK-801-induced hyperactivity associated with regulating inflammation-related genes in the brain.
Ni RJ; Wang YY; Gao TH; Wang QR; Wei JX; Zhao LS; Ma YR; Ma XH; Li T
Zool Res; 2023 May; 44(3):543-555. PubMed ID: 37147908
[TBL] [Abstract][Full Text] [Related]
12. Effect of CSF1R inhibitor on glial cells population and remyelination in the cuprizone model.
Tahmasebi F; Barati S; Kashani IR
Neuropeptides; 2021 Oct; 89():102179. PubMed ID: 34274854
[TBL] [Abstract][Full Text] [Related]
13. CSF1R signaling is a regulator of pathogenesis in progressive MS.
Hagan N; Kane JL; Grover D; Woodworth L; Madore C; Saleh J; Sancho J; Liu J; Li Y; Proto J; Zelic M; Mahan A; Kothe M; Scholte AA; Fitzgerald M; Gisevius B; Haghikia A; Butovsky O; Ofengeim D
Cell Death Dis; 2020 Oct; 11(10):904. PubMed ID: 33097690
[TBL] [Abstract][Full Text] [Related]
14. CSF1/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment.
Fujiwara T; Yakoub MA; Chandler A; Christ AB; Yang G; Ouerfelli O; Rajasekhar VK; Yoshida A; Kondo H; Hata T; Tazawa H; Dogan Y; Moore MAS; Fujiwara T; Ozaki T; Purdue E; Healey JH
Mol Cancer Ther; 2021 Aug; 20(8):1388-1399. PubMed ID: 34088832
[TBL] [Abstract][Full Text] [Related]
15. An Early Microglial Response Is Needed To Efficiently Control Herpes Simplex Virus Encephalitis.
Uyar O; Laflamme N; Piret J; Venable MC; Carbonneau J; Zarrouk K; Rivest S; Boivin G
J Virol; 2020 Nov; 94(23):. PubMed ID: 32938766
[TBL] [Abstract][Full Text] [Related]
16. Peripheral innate immune challenge exaggerated microglia activation, increased the number of inflammatory CNS macrophages, and prolonged social withdrawal in socially defeated mice.
Wohleb ES; Fenn AM; Pacenta AM; Powell ND; Sheridan JF; Godbout JP
Psychoneuroendocrinology; 2012 Sep; 37(9):1491-505. PubMed ID: 22386198
[TBL] [Abstract][Full Text] [Related]
17. [Regulation of colony-stimulating factor 1 receptor inhibitor pexidartinib on the senescence of mouse bone marrow-derived macrophages stimulated by lipopolysaccharide].
Xiao TJ; Zhang J; Kang JB; Li L; Zhan JF; Wei Y; Tian A
Zhonghua Kou Qiang Yi Xue Za Zhi; 2023 Jun; 58(6):575-583. PubMed ID: 37272003
[No Abstract] [Full Text] [Related]
18. CSF1R inhibition by a small-molecule inhibitor is not microglia specific; affecting hematopoiesis and the function of macrophages.
Lei F; Cui N; Zhou C; Chodosh J; Vavvas DG; Paschalis EI
Proc Natl Acad Sci U S A; 2020 Sep; 117(38):23336-23338. PubMed ID: 32900927
[TBL] [Abstract][Full Text] [Related]
19. Microglial depletion and repopulation in brain slice culture normalizes sensitized proinflammatory signaling.
Coleman LG; Zou J; Crews FT
J Neuroinflammation; 2020 Jan; 17(1):27. PubMed ID: 31954398
[TBL] [Abstract][Full Text] [Related]
20. Engineering an inhibitor-resistant human CSF1R variant for microglia replacement.
Chadarevian JP; Lombroso SI; Peet GC; Hasselmann J; Tu C; Marzan DE; Capocchi J; Purnell FS; Nemec KM; Lahian A; Escobar A; England W; Chaluvadi S; O'Brien CA; Yaqoob F; Aisenberg WH; Porras-Paniagua M; Bennett ML; Davtyan H; Spitale RC; Blurton-Jones M; Bennett FC
J Exp Med; 2023 Mar; 220(3):. PubMed ID: 36584406
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
